Physician profile
Denise Hoffman
NPI 1821458217
$7,901.00
in general payments reported to CMS, 2019-2025
37 companies · $1,456 in 2025
The $1,456 reported for 2025 was more than what 89% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,590 · 2022: $1,622 · 2023: $1,821 · 2024: $1,412 · 2025: $1,456.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,590 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,590.01 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $1,325.81 | 2021-2025 | Xtandi, Myrbetriq, Veozah |
| Sumitomo Pharma America, INC. | $1,270.11 | 2023-2025 | Gemtesa |
| Janssen Biotech, INC. | $951.22 | 2021-2025 | Erleada, Balversa |
| Bayer Healthcare Pharmaceuticals INC. | $881.16 | 2021-2025 | |
| Abbvie INC. | $805.80 | 2021-2025 | |
| Pfizer INC. | $460.92 | 2021-2025 | |
| Urovant Sciences INC | $419.98 | 2021-2022 | |
| Medtronic, INC. | $314.19 | 2021-2025 | Interstim |
| Convatec INC. | $248.44 | 2022-2024 | |
| Dentsply Ih Ab | $173.33 | 2024-2025 | Lofric |
| Myriad Genetic Laboratories, INC. | $116.64 | 2021-2023 | Prolaris |
| Merck Sharp & Dohme LLC | $114.95 | 2021-2025 | Keytruda, Lynparza |
| Teleflex LLC | $87.66 | 2022-2025 | Urolift, Barrigel |
| Urogen Pharma, INC. | $64.70 | 2022-2025 | |
| Foundation Medicine, INC. | $54.53 | 2022-2023 | Foundationone Cdx |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $52.90 | 2021 | |
| 180 Medical, INC. | $52.51 | 2023-2024 | |
| Progenics Pharmaceuticals, INC. | $48.40 | 2022-2024 | Pylarify |
| Boston Scientific Corporation | $41.96 | 2021-2025 | Axonics |
| Integra Lifesciences Corporation | $38.52 | 2022 | |
| Axonics, INC. | $35.68 | 2021-2022 | |
| Laborie Medical Technologies Corp. | $33.92 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Antares Pharma, INC. | $29.59 | 2024 | Xyosted |
| Tolmar, INC. | $28.90 | 2023 | |
| Coloplast Corp | $28.90 | 2021-2024 | |
| Profound Medical Corp. | $25.20 | 2025 | Tulsa-Pro |
| Procept Biorobotics Corporation | $21.86 | 2022 | |
| Amgen INC. | $21.36 | 2021 | |
| Blue Earth Diagnostics | $20.87 | 2021 | |
| Rochester Medical Corporation | $19.22 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.03 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $18.88 | 2024 | Exparel |
| Baxter Healthcare | $16.28 | 2021 | |
| Ferring Pharmaceuticals INC. | $15.41 | 2024 | Adstiladrin |
| Novo Nordisk INC | $15.00 | 2021 | |
| Endo Pharmaceuticals INC. | $14.82 | 2021 | |
| Therapeuticsmd, INC. | $12.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denise Hoffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.